Psyence Biomedical (PBM) moves CEO to clinical head as chair becomes CEO

Rhea-AI Filing Summary

Psyence Biomedical Ltd. announced a leadership reorganization. Dr. Neil Maresky has transitioned from his positions as Chief Executive Officer and Director to become the company’s Global Head, Clinical Development, where he will lead global clinical programs, including its Phase 2b clinical trial in Australia. In connection with this change, the company’s Chairman, Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations. The board seat vacated by Dr. Maresky will be filled by a vote of a quorum of directors or at the next annual general meeting of shareholders, in line with applicable law and the company’s governing documents.

Insights

Biotech governance and strategy analyst

Psyence shifts CEO to clinical role while chair takes over corporate leadership.

The company has reassigned Dr. Neil Maresky from Chief Executive Officer and Director to Global Head, Clinical Development. This places an experienced senior executive directly in charge of global clinical development, including the Phase 2b trial in Australia, which appears central to the company’s pipeline.

At the same time, Chairman Jody Aufrichtig has assumed the Chief Executive Officer role, taking responsibility for Nasdaq-related and corporate operations. This concentrates governance and executive authority but keeps leadership within familiar hands rather than bringing in an external CEO.

The board vacancy created by Dr. Maresky’s departure as a director is expected to be filled either by a quorum of directors or at the next annual general meeting of shareholders, as allowed under applicable law and the company’s governing documents. Subsequent company communications may provide more detail on how the new structure supports clinical and corporate priorities.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41937

Psyence Biomedical Ltd. 

(Translation of registrant’s name into English)

121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F     ☐ Form 40-F

Explanatory Note

Psyence Biomedical Ltd (the “Company”) announced that Dr. Neil Maresky has transitioned from his role as Chief Executive Officer and Director of Psyence Biomedical Ltd. to serve as the Company’s Global Head, Clinical Development, where he will lead the Company’s global clinical development initiatives, including its Phase 2b clinical trial in Australia.

In connection with this transition, the Company’s Chairman, Mr. Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations. The vacancy on the Board resulting from Dr. Maresky’s transition will be filled either by way of a vote of a quorum of Directors or at the Company’s next annual general meeting of shareholders, in accordance with applicable law and the Company’s governing documents.

Incorporation by Reference

The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-285542), and any prospectuses or prospectus supplements filed pursuant thereto.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 9, 2025

Psyence Biomedical Ltd.
By:	/s/ Warwick Corden-Lloyd
Name:	Warwick Corden-Lloyd
Title:	Chief Financial Officer

2

FAQ

What leadership changes did Psyence Biomedical Ltd. (PBM) announce?

Psyence Biomedical Ltd. announced that Dr. Neil Maresky has transitioned from his roles as Chief Executive Officer and Director to become Global Head, Clinical Development. The company’s Chairman, Jody Aufrichtig, has assumed the role of Chief Executive Officer and will oversee Nasdaq-related and corporate operations.

What will Dr. Neil Maresky’s new role be at Psyence Biomedical (PBM)?

Dr. Neil Maresky will serve as Psyence Biomedical’s Global Head, Clinical Development. In this position, he will lead the company’s global clinical development initiatives, including its Phase 2b clinical trial in Australia.

Who is the new Chief Executive Officer of Psyence Biomedical Ltd. (PBM)?

The company’s Chairman, Jody Aufrichtig, has assumed the role of Chief Executive Officer. He will oversee Nasdaq-related matters and the company’s corporate operations.

What happens to the board seat vacated by Dr. Maresky at Psyence Biomedical (PBM)?

The vacancy on the board created by Dr. Maresky’s transition from Director will be filled either by a vote of a quorum of directors or at the company’s next annual general meeting of shareholders, in accordance with applicable law and the company’s governing documents.

How is this 6-K related to Psyence Biomedical’s existing registration statement?

The information in this report on Form 6-K is incorporated by reference into Psyence Biomedical Ltd.’s Registration Statement on Form F-3 (File No. 333-285542), including any prospectuses or prospectus supplements filed under that registration.

Which clinical program is highlighted in Psyence Biomedical’s leadership update?

The filing highlights that Dr. Maresky, as Global Head, Clinical Development, will lead Psyence Biomedical’s global clinical initiatives, including its Phase 2b clinical trial in Australia.